GlaxoSmithKline PakistanKAR:GLAXO +1.58%92 PEG Ratio is 0.59 as of Jul. 02, 2026, which is 52% below its 10-year median of 1.23. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.23 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 349 Drug Manufacturers companies, GlaxoSmithKline Pakistan ranks better than 83.95% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for GlaxoSmithKline Pakistan's PEG Ratio or its related term are showing as below:
KAR:GLAXO'
s PEG Ratio Range Over the Past 10 Years
Min: 0.45 Med: 1.23 Max: 12.71
Current: 0.58
During the past 13 years, GlaxoSmithKline Pakistan's highest PEG Ratio was 12.71. The lowest was 0.45. And the median was 1.23.
KAR:GLAXO's PEG Ratio is ranked better than 83.95% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.69
vs KAR:GLAXO: 0.58
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
GlaxoSmithKline Pakistan (KAR:GLAXO) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
GlaxoSmithKline Pakistan PEG Ratio Related Terms
GlaxoSmithKline Pakistan PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:GLAXO vs ZTS, UTHR, VTRS: PEG Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pakistan PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's PEG Ratio distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pakistan's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
GlaxoSmithKline Pakistan (KAR:GLAXO) has a PEG Ratio of 0.59 as of Jul. 02, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on GlaxoSmithKline Pakistan and its competitors. This is 52% below median its historical median of 1.23. Over the past decade, GlaxoSmithKline Pakistan's PEG Ratio has ranged from 0.45 to 12.71. According to the industry distribution chart, GlaxoSmithKline Pakistan ranks #56 out of 349 companies in the Drug Manufacturers industry, placing it in the top 16%.
Is GlaxoSmithKline Pakistan's PEG Ratio too high?
GlaxoSmithKline Pakistan's current PEG Ratio of 0.59 is 52% below median its 10-year median of 1.23. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 12.71. The Drug Manufacturers industry median PEG Ratio is 1.69. GlaxoSmithKline Pakistan's value of 0.59 is 65.1% below this industry median. Based on the distribution chart, GlaxoSmithKline Pakistan ranks #56 out of 349 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pakistan ranks #56 out of 349 companies for PEG Ratio. This places GlaxoSmithKline Pakistan in the top 16% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.69. GlaxoSmithKline Pakistan's value of 0.59 is 65.1% below this benchmark. Historically, GlaxoSmithKline Pakistan's own PEG Ratio has ranged from 0.45 to 12.71 over the past decade. While the company's 10-year median is 1.23 vs. the industry median of 1.69, GlaxoSmithKline Pakistan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.69, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pakistan's current PEG Ratio of 0.59 is 65.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on GlaxoSmithKline Pakistan and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pakistan's current PEG Ratio is 0.59, which is 52% below median its own 10-year median of 1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.23, compared to a current price of ₨376.11 — trading 16% above its estimated fair value. The current PEG Ratio is 0.59, which is 52% below median its 10-year median of 1.23 and 65.1% below the Drug Manufacturers industry median of 1.69. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current PEG Ratio is 0.59 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued.
The current stock price of ₨376.11 is trading 16% above its estimated GF Value™ of ₨324.23.
GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:GLAXO:
PEG Ratio: 0.59 (52% below median its 10-year median of 1.23)
GF Value™: ₨324.23 vs. price of ₨376.11 (16% above fair value)
Industry Position: 65.1% below the Drug Manufacturers median (#56 of 349)
No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score
Get the complete analysis for KAR:GLAXO
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:GLAXO has been successfully added to your 
